диабетическая периферическая нейропатиядиагностика нейропатиигликемический контрольпротивоболевая терапияпатогенетическая терапия1.1. Young M.J., Boulton A.J., MacLeod A.F., Williams D.R., Sonksen P.H. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993;36:150–4.Young M.J., Boulton A.J., MacLeod A.F., Williams D.R., Sonksen P.H. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia 1993;36:150–4.2.2. Tesfaye S., Stevens L.K., Stephenson J.M., Fuller J.H., Plater M., Ionescu-Tirgoviste C., Nuber A., Pozza G., Ward J.D. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia 1996;39:1377–84.Tesfaye S., Stevens L.K., Stephenson J.M., Fuller J.H., Plater M., Ionescu-Tirgoviste C., Nuber A., Pozza G., Ward J.D. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia 1996;39:1377–84.3.3. Cabezas-Cerrato J. Neuropathy Spanish Study Group of the Spanish Diabetes Society (SDS). The prevalence of clinical diabetic polyneuropathy in Spain: a study in primary care and hospital clinic groups.Cabezas-Cerrato J. Neuropathy Spanish Study Group of the Spanish Diabetes Society (SDS). The prevalence of clinical diabetic polyneuropathy in Spain: a study in primary care and hospital clinic groups.4.Diabetologia 1998;41:1263–69.5.4. Abbott C.A., Malik R.A., van Ross E.R., Kulkarni J., Boulton A.J. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 2011;34:2220–4.Abbott C.A., Malik R.A., van Ross E.R., Kulkarni J., Boulton A.J. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 2011;34:2220–4.6.5. Ziegler D., Rathmann W., Dickhaus T., Meisinger C., Mielck A. KORA Study Group. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med 2009;10:393–400.Ziegler D., Rathmann W., Dickhaus T., Meisinger C., Mielck A. KORA Study Group. Neuropathic pain in diabetes, prediabetes and normal glucose tolerance: the MONICA/KORA Augsburg Surveys S2 and S3. Pain Med 2009;10:393–400.7.6. Young L.H., Wackers F.J., Chyun D.A., Davey J.A., Barrett E.J., Taillefer R., Heller G.V., Iskandrian A.E., Wittlin S.D., Filipchuk N., Ratner R.E., Inzucchi S.E. DIAD Investigators. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 2009;301:1547–55.Young L.H., Wackers F.J., Chyun D.A., Davey J.A., Barrett E.J., Taillefer R., Heller G.V., Iskandrian A.E., Wittlin S.D., Filipchuk N., Ratner R.E., Inzucchi S.E. DIAD Investigators. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 2009;301:1547–55.8.7. Tesfaye S., Boulton A.J., Dyck P.J., Freeman R., Horowitz M., Kempler P., Lauria G., Malik R.A., Spallone V., Vinik A., Bernardi L., Valensi P. Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010;33:2285–93.Tesfaye S., Boulton A.J., Dyck P.J., Freeman R., Horowitz M., Kempler P., Lauria G., Malik R.A., Spallone V., Vinik A., Bernardi L., Valensi P. Toronto Diabetic Neuropathy Expert Group. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010;33:2285–93.9.8. Papanas N., Ziegler D. New diagnostic tests for diabetic distal symmetric polyneuropathy. J Diabetes Complications 2011;25:44–51.Papanas N., Ziegler D. New diagnostic tests for diabetic distal symmetric polyneuropathy. J Diabetes Complications 2011;25:44–51.10.9. Tavakoli M., Mojaddidi M., Fadavi H., Malik R.A. Pathophysiology and treatment of painful diabetic neuropathy. Curr Pain Headache Rep 2008;12:192–7.Tavakoli M., Mojaddidi M., Fadavi H., Malik R.A. Pathophysiology and treatment of painful diabetic neuropathy. Curr Pain Headache Rep 2008;12:192–7.11.10. Tavakoli M., Quattrini C., Abbott C., Kallinikos P., Marshall A., Finnigan J., Morgan P., Efron N., Boulton A.J., Malik R.A. Corneal confocal microscopy: a novel noninvasive test to diagnose and stratify the severity of human diabetic neuropathy. Diabetes Care 2010;33:1792–7.Tavakoli M., Quattrini C., Abbott C., Kallinikos P., Marshall A., Finnigan J., Morgan P., Efron N., Boulton A.J., Malik R.A. Corneal confocal microscopy: a novel noninvasive test to diagnose and stratify the severity of human diabetic neuropathy. Diabetes Care 2010;33:1792–7.12.11. Edwards K., Pritchard N., Vagenas D., Russell A., Malik R.A., Efron N. Utility of corneal confocal microscopy for assessing mild diabetic neuropathy: baseline findings of the LANDMark study. Clin Exp Optom. 2012;95:348–54.Edwards K., Pritchard N., Vagenas D., Russell A., Malik R.A., Efron N. Utility of corneal confocal microscopy for assessing mild diabetic neuropathy: baseline findings of the LANDMark study. Clin Exp Optom. 2012;95:348–54.13.12. Oyibo S.O., Prasad Y.D., Jackson N.J., Jude E.B., Boulton A.J. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabet Med 2002;19:870–3.Oyibo S.O., Prasad Y.D., Jackson N.J., Jude E.B., Boulton A.J. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabet Med 2002;19:870–3.14.13. The Diabetes Control and Complications rial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977–86.The Diabetes Control and Complications rial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977–86.15.14. Albers J.W., Herman W.H., Pop-Busui R., Feldman E.L., Martin C.L., Cleary P.A., Waberski B.H., Lachin J.M. Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complications Research Group. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology ofAlbers J.W., Herman W.H., Pop-Busui R., Feldman E.L., Martin C.L., Cleary P.A., Waberski B.H., Lachin J.M. Diabetes Control and Complications Trial / Epidemiology of Diabetes Interventions and Complications Research Group. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of16.Diabetes Interventions and Complications (EDIC) Study. Diabetes Care 2010;33:1090–6.17.15. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 1998;352:837–53.UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 1998;352:837–53.18.16. Boussageon R., Bejan-Angoulvant T., Saadatian-Elahi M., Lafont S., Bergeonneau C., Kassaï B., Erpeldinger S., Wright J.M., Gueyffier F., Cornu C. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011;343:d4169. doi: 10.1136/ bmj.d4169.Boussageon R., Bejan-Angoulvant T., Saadatian-Elahi M., Lafont S., Bergeonneau C., Kassaï B., Erpeldinger S., Wright J.M., Gueyffier F., Cornu C. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011;343:d4169. doi: 10.1136/ bmj.d4169.19.17. Callaghan B.C., Little A.A., Feldman E.L., Hughes R.A. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database of Systematic Reviews 2012 Jun 13;6:CD007543.Callaghan B.C., Little A.A., Feldman E.L., Hughes R.A. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database of Systematic Reviews 2012 Jun 13;6:CD007543.20.18. Ziegler D., Hidvégi T., Gurieva I., Bongardt S., Freynhagen R., Sen D., Sommerville K. Lacosamide SP743 Study Group. Efficacy and safety of lacosamide in painful diabetic neuropathy. Diabetes Care. 2010;33:839–41.Ziegler D., Hidvégi T., Gurieva I., Bongardt S., Freynhagen R., Sen D., Sommerville K. Lacosamide SP743 Study Group. Efficacy and safety of lacosamide in painful diabetic neuropathy. Diabetes Care. 2010;33:839–41.21.19. Shaibani A.I., Pope L.E., Thisted R., Hepner A. Efficacy and safety of dextromethorphan/quinidine at two dosage levels for diabetic neuropathic pain: a doubleblind, placebo-controlled, multicenter study. Pain Med 2012;13:243–54.Shaibani A.I., Pope L.E., Thisted R., Hepner A. Efficacy and safety of dextromethorphan/quinidine at two dosage levels for diabetic neuropathic pain: a doubleblind, placebo-controlled, multicenter study. Pain Med 2012;13:243–54.22.20. Gilron I., Bailey J.M., Tu D., Holden R.R., Weaver D.F., Houlden R.L. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352:1324–34.Gilron I., Bailey J.M., Tu D., Holden R.R., Weaver D.F., Houlden R.L. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med 2005;352:1324–34.23.21. Mason L., Moore R.A., Derry S., Edwards J.E., McQuay H.J. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 2004;328:991–5.Mason L., Moore R.A., Derry S., Edwards J.E., McQuay H.J. Systematic review of topical capsaicin for the treatment of chronic pain. BMJ 2004;328:991–5.24.22. Davies P.S., Galer B.S. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs 2004;64:937–47.Davies P.S., Galer B.S. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs 2004;64:937–47.25.23. Campbell C.M., Kipnes M.S., Stouch B.C., Brady K.L., Kelly M., Schmidt W.K., Petersen K.L., Rowbotham M.C., Campbell J.N. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain 2012 Jun 8 [Epub ahead of print].Campbell C.M., Kipnes M.S., Stouch B.C., Brady K.L., Kelly M., Schmidt W.K., Petersen K.L., Rowbotham M.C., Campbell J.N. Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy. Pain 2012 Jun 8 [Epub ahead of print].26.24. Ziegler D. Current concepts in the management of diabetic polyneuropathy. Curr Diabetes Rev 2011;7:208–20.Ziegler D. Current concepts in the management of diabetic polyneuropathy. Curr Diabetes Rev 2011;7:208–20.27.25. Kempler P., Stirban A., Tesfaye S., Czupryniak L., Gurieva I., Mankovsky B.N., Spallone V., Veresiu A., Schnell O. Need for pathogenetically oriented therapy of neuropathy in diabetes mellitus. Diabetes Stoffwechsel und Herz 2011;20:143–150.Kempler P., Stirban A., Tesfaye S., Czupryniak L., Gurieva I., Mankovsky B.N., Spallone V., Veresiu A., Schnell O. Need for pathogenetically oriented therapy of neuropathy in diabetes mellitus. Diabetes Stoffwechsel und Herz 2011;20:143–150.28.26. Boulton A.J. Whither clinical research in diabetic sensorimotor peripheral neuropathy? Problems of end point selection for clinical trials. Diabetes Care 2007;30:2752–3.Boulton A.J. Whither clinical research in diabetic sensorimotor peripheral neuropathy? Problems of end point selection for clinical trials. Diabetes Care 2007;30:2752–3.29.27. Dyck P.J., Norell J.E., Tritschler H., Schuette K., Samigullin R., Ziegler D., Bastyr E.J. 3rd, Litchy W.J., O'Brien P.C. Challenges in design of multicenter trials: end points assessed longitudinally for change and monotonicity. Diabetes Care 2007;30:2619–25.Dyck P.J., Norell J.E., Tritschler H., Schuette K., Samigullin R., Ziegler D., Bastyr E.J. 3rd, Litchy W.J., O'Brien P.C. Challenges in design of multicenter trials: end points assessed longitudinally for change and monotonicity. Diabetes Care 2007;30:2619–25.30.28. Goto Y., Hotta N., Shigeta Y., Sakamoto N., Kikkawa R. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebocontrolled double-blind study. Biomed Pharmacother 1995;49:269–77.Goto Y., Hotta N., Shigeta Y., Sakamoto N., Kikkawa R. Effects of an aldose reductase inhibitor, epalrestat, on diabetic neuropathy. Clinical benefit and indication for the drug assessed from the results of a placebocontrolled double-blind study. Biomed Pharmacother 1995;49:269–77.31.29. Hotta N., Akanuma Y., Kawamori R., Matsuoka K., Oka Y., Shichiri M., Toyota T., Nakashima M., Yoshimura I., Sakamoto N., Shigeta Y. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor- Diabetes Complications Trial. Diabetes Care 2006;29:1538–44.Hotta N., Akanuma Y., Kawamori R., Matsuoka K., Oka Y., Shichiri M., Toyota T., Nakashima M., Yoshimura I., Sakamoto N., Shigeta Y. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on diabetic peripheral neuropathy: the 3-year, multicenter, comparative Aldose Reductase Inhibitor- Diabetes Complications Trial. Diabetes Care 2006;29:1538–44.32.30. Bril V., Hirose T., Tomioka S., Buchanan R. Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care 2009;32:1256–60.Bril V., Hirose T., Tomioka S., Buchanan R. Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care 2009;32:1256–60.33.31. Vincent A.M., Callaghan B.C., Smith A.L., Feldman E.L. Diabetic neuropathy: cellular mechanisms asVincent A.M., Callaghan B.C., Smith A.L., Feldman E.L. Diabetic neuropathy: cellular mechanisms as34.therapeutic targets. Nat Rev Neurol 2011;7:573–83.35.32. Ziegler D., Nowak H., Kempler P., Vargha P., Low P.A. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a metaanalysis. Diabet Med 2004;21:114–21.Ziegler D., Nowak H., Kempler P., Vargha P., Low P.A. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a metaanalysis. Diabet Med 2004;21:114–21.36.33. Mijnhout G.S., Kollen B.J., Alkhalaf A., Kleefstra N., Bilo H.J. Alpha-lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. Int J Endocrinol 2012;2012:456279.Mijnhout G.S., Kollen B.J., Alkhalaf A., Kleefstra N., Bilo H.J. Alpha-lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. Int J Endocrinol 2012;2012:456279.37.34. Ziegler D., Ametov A., Barinov A., Dyck P.J., Gurieva I., Low P.A., Munzel U., Yakhno N., Raz I., Novosadova M., Maus J., Samigullin R. Oral treatment with alphalipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006;29:2365–70.Ziegler D., Ametov A., Barinov A., Dyck P.J., Gurieva I., Low P.A., Munzel U., Yakhno N., Raz I., Novosadova M., Maus J., Samigullin R. Oral treatment with alphalipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006;29:2365–70.38.35. Ziegler D., Low P.A., Litchy W.J., Boulton A.J., Vinik A.I., Freeman R., Samigullin R., Tritschler H., Munzel U., Maus J., Schütte K, Dyck P.J. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 2011;34:2054–60.Ziegler D., Low P.A., Litchy W.J., Boulton A.J., Vinik A.I., Freeman R., Samigullin R., Tritschler H., Munzel U., Maus J., Schütte K, Dyck P.J. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 2011;34:2054–60.39.36. Machicao F., Muresanu D.F., Hundsberger H., Pflüger M., Guekht A. Pleiotropic neuroprotective and metabolic effects of Actovegin's mode of action. J Neurol Sci 2012; doi: 0.1016/j. jns.2012.07.069.Machicao F., Muresanu D.F., Hundsberger H., Pflüger M., Guekht A. Pleiotropic neuroprotective and metabolic effects of Actovegin's mode of action. J Neurol Sci 2012; doi: 0.1016/j. jns.2012.07.069.40.37. Ziegler D., Movsesyan L., Mankovsky B., Gurieva I., Abylaiuly Z., Strokov I. Treatment of symptomaticZiegler D., Movsesyan L., Mankovsky B., Gurieva I., Abylaiuly Z., Strokov I. Treatment of symptomatic41.polyneuropathy with actovegin in type 2 diabetic patients. Diabetes Care 2009;32:1479–84.42.38. Malik R.A., Williamson S., Abbott C., Carrington A.L., Iqbal J., Schady W., Boulton A.J. Effect of angiotensinconverting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998;352:1978–81.Malik R.A., Williamson S., Abbott C., Carrington A.L., Iqbal J., Schady W., Boulton A.J. Effect of angiotensinconverting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998;352:1978–81.43.39. Ruggenenti P., Lauria G., Iliev I.P., Fassi A., Ilieva A.P., Rota S., Chiurchiu C., Barlovic D.P., Sghirlanzoni A., Lombardi R., Penza P., Cavaletti G., Piatti M.L., Frigeni B., Filipponi M., Rubis N., Noris G., Motterlini N., Ene-Iordache B., Gaspari F., Perna A., Zaletel J., Bossi A., Dodesini A.R., Trevisan R., Remuzzi G. DEMAND Study Investigators. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension 2011;58:776–83.Ruggenenti P., Lauria G., Iliev I.P., Fassi A., Ilieva A.P., Rota S., Chiurchiu C., Barlovic D.P., Sghirlanzoni A., Lombardi R., Penza P., Cavaletti G., Piatti M.L., Frigeni B., Filipponi M., Rubis N., Noris G., Motterlini N., Ene-Iordache B., Gaspari F., Perna A., Zaletel J., Bossi A., Dodesini A.R., Trevisan R., Remuzzi G. DEMAND Study Investigators. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension 2011;58:776–83.44.40. Akahori H., Takamura T., Hayakawa T., Ando H., Yamashita H., Kobayashi K. Prostaglandin E1 in lipid microspheres ameliorates diabetic peripheral neuropathy: clinical usefulness of Semmes-Weinstein monofilaments for evaluating diabetic sensory abnormality. Diabetes Res Clin Pract 2004;64:153–9.Akahori H., Takamura T., Hayakawa T., Ando H., Yamashita H., Kobayashi K. Prostaglandin E1 in lipid microspheres ameliorates diabetic peripheral neuropathy: clinical usefulness of Semmes-Weinstein monofilaments for evaluating diabetic sensory abnormality. Diabetes Res Clin Pract 2004;64:153–9.45.41. Miyata T., Yamada N., Miyachi Y. Efficacy by ulcer type and safety of lipo- PGE1 for Japanese patients with diabetic foot ulcers. J Atheroscler Thromb 2010;17:805–16.Miyata T., Yamada N., Miyachi Y. Efficacy by ulcer type and safety of lipo- PGE1 for Japanese patients with diabetic foot ulcers. J Atheroscler Thromb 2010;17:805–16.46.42. Stracke H., Gaus W., Achenbach U., Federlin K., Bretzel R.G. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebocontrolled clinical study. Exp Clin Endocrinol Diabetes 2008;116:600–5.Stracke H., Gaus W., Achenbach U., Federlin K., Bretzel R.G. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebocontrolled clinical study. Exp Clin Endocrinol Diabetes 2008;116:600–5.47.43. Haupt E., Ledermann H., Köpcke W. Benfotiamine in the treatment of diabetic polyneuropathy – a three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther 2005;43:71–7.Haupt E., Ledermann H., Köpcke W. Benfotiamine in the treatment of diabetic polyneuropathy – a three-week randomized, controlled pilot study (BEDIP study). Int J Clin Pharmacol Ther 2005;43:71–7.48.44. Winkler G., Pál B., Nagybéganyi E., Ory I., Porochnavec M., Kempler P. Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy. Arzneimittelforschung 1999;49:220–4.Winkler G., Pál B., Nagybéganyi E., Ory I., Porochnavec M., Kempler P. Effectiveness of different benfotiamine dosage regimens in the treatment of painful diabetic neuropathy. Arzneimittelforschung 1999;49:220–4.49.45. Fraser D.A., Diep L.M., Hovden I.A., Nilsen K.B., Sveen K.A., Seljeflot I., Hanssen K.F. The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebocontrolled trial. Diabetes Care 2012;35:1095–7.Fraser D.A., Diep L.M., Hovden I.A., Nilsen K.B., Sveen K.A., Seljeflot I., Hanssen K.F. The effects of long-term oral benfotiamine supplementation on peripheral nerve function and inflammatory markers in patients with type 1 diabetes: a 24-month, double-blind, randomized, placebocontrolled trial. Diabetes Care 2012;35:1095–7.50.46. Ekberg K., Johansson B.L. Effect of C-peptide on diabetic neuropathy in patients with type 1 diabetes. Exp Diabetes Res 2008:2008:457912.Ekberg K., Johansson B.L. Effect of C-peptide on diabetic neuropathy in patients with type 1 diabetes. Exp Diabetes Res 2008:2008:457912.51.47. Ekberg K., Brismar T., Johansson B.L., Lindström P., Juntti-Berggren L., Norrby A., Berne C., Arnqvist H.J., Bolinder J., Wahren J. C-peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care 2007;30:71–6.Ekberg K., Brismar T., Johansson B.L., Lindström P., Juntti-Berggren L., Norrby A., Berne C., Arnqvist H.J., Bolinder J., Wahren J. C-peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care 2007;30:71–6.